Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4697-4702

  Berruti, Alfredo ^a   Cerutti, Stefania ^a   Fasolis, Giuseppe ^b   Sperone, Paola ^a   Tarabuzzi, Roberto ^b   Bertetto, Oscar ^c   Pagani, Giovanni ^d   Zolfanelli, Roberto ^e   Pallotti, Silvio ^f   Bumma, Cesare ^c   Fontana, Dario ^b   Rosseti, Salvatore Rocca ^c   Dogliotti, Luigi ^b   Angeli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d Ospedale San Biagio   (Italy)

^e Department of Neurology   (Italy)

^f Azienda Regionale USL 20   (Italy)

Author keywords

Alkaline phosphatase; Bone metastases; Goserelin; Mitomycin C; Osteoblastic flare; Serum prostate cancer; Therapy

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; GOSERELIN; MITOMYCIN C;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOBLAST; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; ALKALINE PHOSPHATASE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME TESTS; GOSERELIN; HUMANS; ITALY; MALE; MITOMYCIN; OSTEOBLASTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 6844252891     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Crocetti E, Buiatti E, Amorosi A: Prostate cancer: population-based survival rates in central Italy. Tumori 81: 81-85, 1995.
2. Griffiths K, Eaton CL, Harper ME, Turkes A, Peeling WB: Hormonal treatment of advanced disease. Sem Oncol 21: 672-687, 1994.
3. Boccardo F, Granetto C: Chemotherapy in advanced stage prostate cancer: an overview. Forum Trends Exp Clin Med 6.2 (suppl 2): 42-45, 1996.
4. Kubota Y, Nakada T, Imai K, Yamanaka H, Sakai H, Saito Y, Tomaru Y, Kitamura K, Sugano O, Sasagawa I: Chemo-endocrine-therapy in patients with stage 2 prostate cancer. Prostate 26: 50-54, 1995.
5. Murphy GP, Beckley S, Brady MF, Chu M, deKerion J, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes E, Prout GR, Schmidt JD, Scott WW, Slack NH, Soloway MS: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 57: 1264-1272, 1983.
6. Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28: 36-40, 1986.
7. Huben RP, Murphy GP: A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer ofthe prostate. Cancer 62: 1881-1887, 1988.
8. Vandenbroucke F, Van Poppel H, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuystel L, Paridaens R, Baert L: Interim analysis on a randomized trial of mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer. Am J Clin Oncol (CCT) 18: 263-266, 1995.
9. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 41: 5070-5075, 1981.
10. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, De Pauw, Sylvester R: Mitomycin C in metastatic prostate cancer. Report on a EORTC phase II study. World J Urol 4: 182-185, 1986.
11. Berruti A, Fara E, Fasolis G, Randone D, Tarabuzzi R, Mosele G, Bertetto O, Fontana D, Rocca Rossetti S, Dogliotti L. Somministrazione orale di estramustina ed etoposide nel trattamento di pazienti con carcinoma prostatico avanzato in progressione dopo soppressione androgenica. Forum Trends Exp Clin Med 6.2 (suppl 2): 63-67, 1996.
12. ∼ Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994.
13. Aabo K: Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization ofthe reporting results. Eur J Cancer 23: 231-236, 1987.
14. Miller JI, Ahman FR, Drach DW, Emerson SS, Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
15. Sridhara R, Eisenberg MA, Sinibaldi VJ, Reyno LM, Egorin MJ: Evaluation of Prostate Specific Antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953, 1995.
16. Urwin GH, Percival R, Yates AJ, Watson ME, Couch M, McDonald B, Forrest ARW, Williams JL, Kanis JA: Biochemical markers and skeletal metabolism in carcinoma of the prostate. Use of decision matrix theory and ROC analysis. Brit J Urol 57: 711-717, 1985.
17. Van Hoof VO, De Broe ME: Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 31: 197-293, 1994.
18. Ali SY, Sajdera SW, Anderson HC: Isolation and characterization of calcifying vesicles from epiphyseal cartilage. Proc Natl Acad Sci 67: 1513-1520, 1970.
19. Garrido JC, Aguayo FJ, Moreno CA: Comparison of three bone alkaline phosphatase quantification methods in patients with increased alkaline activities. Clin Chem 38: 1165-1166, 1992.
20. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, Miller PD, Mizrahi I, Darte C, Kress BC, Christenson RH: Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 40: 822-828, 1994.
21. Delmas PD: Biochemical markers of bone turnover. J Bone Miner Res 8: S549-S555, 1993.
22. Piovesan A, Berruti A, Torta M, Cannone R, Sperone P, Panero A, Gorzegno G, Termine A, Dogliotti L, Angeli A: Comparison of assays of total and bone-specific alkaline phosphatase in the assessement of osteoblast activity in patients with metastatic bone disease. Calcif Tissue Int 1997, (in press).
23. Woitge WH, Seibel MJ, Ziegler R: Comparison of total and bone-specific alkaline phosphatase in patients with non skeletal disorders or metabolic bone disease. Clin Chem 42: 1796-1804, 1996.
24. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P, Dogliotti L, Angeli A: Biochemical evaluation of hone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 73: 1581-1587, 1996.
25. Berruti A, Osella G, Raucci CA, Roncari A, Dogliotti L: Transient increase in total serum, alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases. Oncology 50: 218-221, 1993.
26. Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I, Rubens RD: Biochemical monitoring predicts response in bone metastases to treatment. Br J Cancer 58: 205-210, 1987.
27. Coleman RE, Mashiter G, Whitaker KB. Moss DW, Rubens RD, Fogelman I: Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29: 1354-1358, 1988.
28. Vogel CL, Schoenfelter J, Shemano I, Hayes DF, Gams RA: Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13: 1123-1128, 1995.
29. Mackintosh J, Simes J, Raghavan D, Pearson B: Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". Br J Urol 66: 88-93, 1990.
30. Pelger RCM, Lycklama GAB, Nijeholt A, Zwinderman AH, Papapoulos SE, Hamdy NAT: The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression free survival in prostatic carcinoma. J Urol 156: 122-126, 1996.
31. Fontana D, Bertetto O, Fasolis G, Berrati A, Tarabuzzi R, Pagani G, Buniva T, Zolfanelli R, Pallotti S, Frezzotti L, Bumma C, Rocca Rossetti S, Dogliotti L: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 1997, in press.
32. Norusis MJ: SPSS/PC+ Base manual for the IBM PC/XT/AT and PS/2. SPSS Inc. Chicago, 1988.
33. Sundkvist GM, Algren L, Lilja B, Mattsson S, Ahrahamsson PA: Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy. Eur J Nucl Med 16: 671-675, 1990.
34. Smith JA: Luteinizing hormone-releasing hormone (LHRH) analogs in treatment of prostatic cancer: Clinical Perspective. Urology 27 (Suppl): 9-15, 1986.
35. Pontes JE: The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression free survival in prostatic carcinoma. Editorial Comment. J Urol 156: 122-126, 1996.
36. Killian CS, Vargas FP, Pontes EJ, Beckley S, Slack NH, Murphy GP, Chu TM: The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer. Prostate 2: 187-191, 1981.
37. Carlson K, Simonson B, Ljunghall S: Acute effects of high dose chemotherapy followed by - bone marrow transplantation on serum markers of bone metabolism. Calcif Tissue Int 55: 408-411, 1994.
38. Berruti A, Raucci CA, Sperone P, Torta M, Piovesan A, Cannone R, Dogliotti L, Angeli A: serial evaluation of bone formation markers in breast cancer patients with bone metastases. Effect of chemotherapy with or without pamidronate. Bone 17: 607 (Meeting Abstract), 1995.